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Abstract
Traumatic brain injury (TBI) is an important public health problem with an increasing incidence in the last years. Relatively 
few cases are fatal; most individuals will survive and, in the long-term, the sequalae of TBI will include neuroendocrine 
dysfunctions with a much higher frequency than previously suspected. Patients who develop hypopituitarism after TBI present 
manifestations due to the number of deficient hormones, severity of hormonal deficiency, and the duration of hypopituitarism 
without diagnosis and treatment. The clinical spectrum of hypopituitarism is very large and many signs and symptoms of 
TBI survivors such as fatigue, concentration difficulties, depressive symptoms are nonspecific and overlap with symptoms 
of post-traumatic stress disorder and variably severe hypopituitarism related to brain damage remaining undiagnosed. This 
can explain why the diagnosis of hypopituitarism is often missed or delayed after this condition with potentially serious and 
hazardous consequences for the affected patients. Moreover, clinical experience cumulatively suggests that TBI-associated 
hypopituitarism is associated with poor recovery and worse outcome, since post-traumatic hypopituitarism is independently 
associated with cognitive impairment, poor quality of life, abnormal body composition, and adverse metabolic profile. In 
the present review, the current data related to clinical consequences of pituitary dysfunction after TBI in adult patients and 
therapeutic approaches are reported.
Keywords Traumatic brain injury · Hypopituitarism · Replacement therapy
Introduction
Traumatic brain injury (TBI) is defined as an alteration in 
brain function caused by an external force. TBI is a lead-
ing cause of death and disability, being a major public 
health problem nowadays [1]. A recent meta-analysis sug-
gested that the incidence is increasing and affects 134–618 
persons per 100,000 per year with the highest incidence 
appearing in adult men [2]. Relatively few cases are fatal, 
and most individuals will survive beyond the event such 
that neuroendocrine dysfunctions may occur with a much 
higher frequency than previously suspected [1]. The reported 
prevalence of chronic anterior pituitary hormone deficiency 
following TBI reportedly exceeds 25%, and accounts for 
approximately 5% of all causes of hypopituitarism [3]. Neu-
roendocrine dysfunction due to TBI was described for the 
first time in 1918 [4], though the syndrome did not garner 
significant attention until the turn of this century. Since then, 
a large body of research has demonstrated the importance 
of post traumatic hypopituitarism [3, 5–19] and, over the 
past 15 years, numerous studies have documented a high 
rate of pituitary gland dysfunction following moderate or 
severe TBI with the evidence that hypopituitarism contrib-
utes significantly to the morbidity and possibly mortality 
in TBI patients [20]. Direct mechanical trauma and vascu-
lar/hypoxic insult to the hypothalamus, pituitary stalk or 
pituitary gland, compression from hemorrhage, edema or 
increased intracranial pressure are among the factors pro-
posed to explain the pathophysiology of TBI-induced pitui-
tary dysfunction. Genetic and immunologic studies have 
given new insight into the pathophysiology of TBI-induced 
pituitary dysfunction, since the Apolipoprotein E3/E3 
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genotype decreases the risk of TBI-induced hypopituitarism 
and anti-pituitary antibodies and anti-hypothalamic antibod-
ies may have a role in the development and/or worsening 
of hypopituitarism in patients with TBI [21–23]. In spite 
of the large literature on this topic [24], pituitary disorders 
are a frequently overlooked complication of TBI. A group 
of experts reviewed the evidences on TBI-induced hypopi-
tuitarism and concluded that it is often underdiagnosed, and 
that medical community is not adequately informed about 
the importance of this problem [25]. In fact, many symptoms 
of TBI survivors such as fatigue, concentration difficulties, 
and depressive symptoms are nonspecific and overlap with 
symptoms commonly attributed to post-traumatic stress 
disorder (PTSD), leaving a consistent of cases of hypopitui-
tarism related to brain damage undiagnosed [25, 26]. This 
would explain why the diagnosis of hypopituitarism is often 
missed or delayed after these conditions with potentially 
serious and sometimes life-threatening consequences for 
the affected patients. Moreover, recent findings suggest that 
hypopituitarism after TBI is associated with poor recovery 
and worse outcome, since post-traumatic hypopituitarism is 
independently associated with poor quality of life, abnormal 
body composition, and adverse metabolic profile [27–29].
The aim of the present review is to update the current data 
regarding the clinical consequences of pituitary hormone 
deficiencies after TBI and the treatment of TBI-induced 
hypopituitarism in adulthood.
Clinical features
Patients who develop hypopituitarism after TBI present 
manifestations due to the number of deficient hormones, 
severity of hormonal deficiency, and the duration of hypo-
pituitarism without diagnosis and treatment. Independent 
of the underlying cause, the clinical spectrum of hypopi-
tuitarism is very large and varies from some nonspecific 
complaints including fatigue, anorexia, arthralgia, and 
headache, to life-threatening conditions which necessi-
tate emergency admission such as adrenal crisis, water 
and salt imbalance, and severe hypoglycemia [30]. Over-
all, the most frequent abnormalities reported are growth 
hormone deficiency (GHD), adrenocorticotropic hormone 
(ACTH) insufficiency, and gonadotropin deficiency [1, 3, 
8, 31]. Because of the mild and nonspecific manifestations 
recorded in the majority of patients with hypopituitarism 
due to different causes including TBI, hypopituitarism 
remains undiagnosed in most TBI patients and thereby 
untreated [23]. The symptoms of hypopituitarism are sum-
marized in Table 1 [30, 32].
In TBI, we can distinguish an acute phase, that is day 
1–14 post event, and the chronic phase, that is 3–6 months 
post TBI. Hormonal patterns occurring during the acute 
phase have been investigated in order to understand whether 
the changes are related to critical illness or are TBI-specific, 
and it seems that most of the hormonal alterations in the 
acute phase reflect the acute adaptive response to the trau-
matic event and are, therefore, transient [15, 19]. The most 
clinically significant abnormalities in the acute phase of TBI 
are ACTH- cortisol deficiency and salt and water imbalance 
[11, 33, 34]. Acute-phase hypocortisolism is potentially life 
threatening. In fact, a number of studies have shown an asso-
ciation between increased morbidity or mortality and acute 
post-traumatic hypoadrenalism [33–35]. However, some 
of these early abnormalities are only transient: recovery of 
hypoadrenalism can be achieved in 50% of cases, while dia-
betes insipidus dissipates in up to 90% of cases [11, 15]. The 
full recovery may thus happen within days or weeks after 
TBI, while new pituitary hormone deficiency may become 
apparent in the post-acute phase [10, 36].
Table 1  Clinical features and investigative findings of hypopituitarism
ACTH adrenocorticotropic hormone, TSH thyrotropic hormone, FSH follicle-stimulating hormone, LH luteinising Hormone, GH growth hor-




ACTH Fatigue, pallor, anorexia, weight loss
Life-threatening adrenal crises: weakness, dizziness, nausea, 
vomiting, circulatory collapse, fever, shock
Hypoglycaemia, hypotension, anaemia, lymphocytosis, eosino-
philia, hyponatraemia
TSH Tiredness, cold intolerance, constipation, hair loss, dry skin, 
hoarseness, cognitive slowing
Weight gain, bradycardia, hypotension
FSH/LH Men: loss of libido, impaired sexual function, mood impairment, 
loss of facial, scrotal, and trunk hair, weight changes
Women: oligoamenorrhea, loss of libido, dispareunya, infertility, 
weight changes
Decreased muscle mass, osteoporosis, anaemia
Osteoporosis
GH Decreased muscle strength, visceral obesity, fatigue, decreased 
quality of life, impairment of attention and memory
Dyslipidemia, premature atherosclerosis, decreased muscle mass
ADH Polyuria, polydipsia Decreased urine osmolality, hypernatraemia, polyuria
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Gonadotropin and growth-hormone deficiencies, instead, 
cause chronic morbidity.
Among the pituitary hormone deficiencies, GH deficiency 
appears to be the commonest deficiency in those who were 
tested 6 months or more following the event [9, 32, 37, 38]. 
Long-term adult GH deficiency is associated with clinical 
and biochemical findings compatible with GHD syndrome, 
comprehending reduced lean body mass, reduced bone min-
eral density, impaired cardiac function and decreased quality 
of life (QoL) [30, 39].
In addition to the classic symptoms of hypopituitarism 
described, there is a rapidly growing body of literature sug-
gesting that hypopituitarism following TBI has a negative 
impact on cognition, and recent data seem to confirm that 
anterior pituitary hormone deficiency has a negative impact 
on functional outcome at 6 months post TBI, as assessed 
by mini-mental state exam and functional independence 
measure scores [20]. Other studies have found a correlation 
between post-TBI hypopituitarism and unfavorable meta-
bolic and body composition profiles with associated lower 
QoL scores [27, 39] as well as decreased exercise capacity 
[12] and then neuropsychiatric complications [13]. Intui-
tively, these complications could lead to a vicious circle and 
be thus coexistent.
Cognitive impairment
Neuropsychiatric symptoms after TBI are common and 
impair QoL of survivors. Hypotheses concerning the patho-
logical roots of these sequelae have pointed to a number of 
causes, of which post traumatic hypopituitarism, and par-
ticularly post-TBI GHD, is likely particularly important.
Cognitive impairment after TBI ranges from attention, 
memory, information processing speed and executive func-
tions to even more robust functions, such as language and 
visuospatial constructional skills. Such deficits can severely 
impact an individual’s ability to return to an active, inde-
pendent role in society. In this scenario, the cognitive mani-
festations of hormone deficiencies can be quite obvious, or 
incredibly subtle. The consequences of these deficiencies 
may be minor, or they may keep the individual from func-
tioning independently in society, and these deficiencies may 
be masked by what has been previously attributed to the 
intrinsic signs and symptoms of the TBI itself. Moreover, 
symptoms associated with pituitary dysfunction overlap 
considerably with those of PTSD, as cognitive deficiencies, 
mood and anxiety disorders, sleep problems, diminished 
QoL, deleterious changes in metabolism and body com-
position, and increased cardiovascular mortality [40]. The 
differential diagnosis is very important since, when such 
symptoms are due to hypopituitarism, they may be alleviated 
by hormone replacement. The diagnosis and treatment of 
post-traumatic hypopituitarism may, therefore, play a sig-
nificant role in the cognitive recovery from a brain injury 
[29, 39].
So, the disruption of anterior pituitary post TBI is related 
to cognitive impairment and each deficient hormone can 
contribute to this symptomatology.
Regarding HPA axis, given its role in response to stress, 
a relationship between cortisol levels and psychiatric symp-
toms (particularly symptoms of anxiety) seems reasonable. 
In fact, a complex relationship among post-injury cortisol 
levels, injury severity, and the development of anxiety is 
reported in literature. In particular, the results of the studies 
by Tanriverdi et al. [41] and by Flesher et al. [42] suggest 
that injury severity is antagonistic to an elevated cortisol 
response. It is possible that cortisol response is related to 
stressful recollections of the incident that caused the injury. 
Factors such as loss of consciousness and post- traumatic 
amnesia may prevent awareness of the injury and its poten-
tial tragic consequences, thus precluding an associated stress 
response.
Concerning thyroid hormone, hypothyroidism is asso-
ciated with both disturbed neuropsychologic well-being 
and neurocognitive functioning [43]; in fact, hypothyroid 
patients typically demonstrate the types of deficits so com-
monly seen following TBI, such as executive functioning, 
speed of information processing, and aspects of memory, 
predominantly short-term memory [44]. Evidence from ani-
mal models suggests a possible mechanism linking thyroid 
function to cognition as well as the positive effects of thyroid 
hormone replacement on cognition following brain injury. 
The data suggest that thyroid hormone regulates neurogen-
esis in the rat hippocampus, providing a logical role for the 
thyroid hormone in learning and memory [45].
Hypogonadism is also associated with cognitive dys-
function [46]. The results of testosterone supplementation 
in hypogonadal males have shown improvement in some 
domains of memory [46, 47]. Moreover, of the individuals 
who have sustained TBI, those with lower testosterone levels 
also appear to have an increased risk for Alzheimer’s disease 
[48]. However, studies on cognitive improvement following 
estrogen supplementation in females have yielded conflicting 
results [49, 50]. So, presently, the issue of cognitive changes 
with sex hormone supplementation remains unresolved [51].
According with these evidences, it seems that the cog-
nitive dysfunctions following TBI are not only the result 
of brain injury itself but also of hypopituitarism and, in 
particular, GHD may result in cognitive abnormalities. In 
patients with chronic hypopituitarism not secondary to head 
trauma, similar complaints of fatigue, depression, anxiety, 
and loss of emotional well-being also arise. GHD in par-
ticular is associated with diminished psychological health 
and decreased QoL in adults, and since about 30 years ago 
has been designated as its own specific clinical syndrome 
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[52]. Research has revealed significant decreases in energy 
and emotional lability, heightened sense of social isolation, 
greater difficulties with sexual relationships, decreased QoL, 
and greater psychological distress in untreated versus treated 
GHD [39, 53]. Furthermore, it has been repeatedly dem-
onstrated that post-TBI GHD is similarly associated with 
impaired motivation, depression, and decreased QoL, with 
no convincing role of trauma severity [54, 55]. Therefore, it 
comes as no surprise that these same symptoms after head 
trauma that were once regarded simply under the umbrella 
of post-concussive syndrome are being reconsidered in the 
context of post traumatic hypopituitarism and specifically 
post-TBI GHD. Moreover, many symptoms of PTSD overlap 
with those of TBI, and questions whether neuroendocrine 
pathologies may contribute to PTSD in the setting of head 
trauma have arisen [40].
The mechanism by which GH may affect cognition is 
not well-understood but greater cognitive dysfunction has 
been reported in patients with TBI who have GH deficiency 
compared to those with normal GH levels [54]. In particu-
lar, three recent studies evaluated neurobehavioral and QoL, 
demonstrating that those patients with GH deficiency had 
higher rates of depression, impaired cognitive performance, 
greater deficits in simple attention, more intrusions and 
repetitions on a memory task, increased reaction time, and 
greater emotional disruption [54–56]. In particular, patients 
with GHD after TBI showed lower QoL in the domains of 
general health, physical health, and emotional health when 
compared to subjects with normal pituitary function [54]: 
Health-related quality of life (HRQL) and Quality of Life 
Assessment of GHD in Adults (QoL-AGHDA) in TBI survi-
vors are worsened, independent of pituitary functions, when 
compared with healthy controls. In the study by Popovic 
et al., GH peak was significantly correlated with short- and 
long-term memory deficits in the patients with GHD due 
to TBI and also a correlation between lower IGF-I levels 
and visual memory was reported [12]. Moreover, has been 
recently reported that decreased IGF-I levels seem to indi-
cate an increased risk of developing Alzheimer’s disease 
[57]. In an experimental study, serum IGF-I levels were 
found to be decreased in both the early and late periods of 
TBI and low levels of serum IGF-I were correlated with 
hippocampal neuron loss and spatial memory deficits [58].
Metabolic alterations
Hypopituitarism, in general, and GHD, in particular, are 
associated with a number of metabolic alterations [59]. Con-
sequently, it is feasible that TBI patients with neuroendo-
crine dysfunction may have metabolic alterations; however, 
few studies have evaluated these issues, including changes 
in body composition and BMI, lipid profile, glucose metabo-
lism, and hypertension [27, 28, 60].
The study by Klose et  al. demonstrated that patients 
with hypopituitarism after TBI (due to acute road accident) 
have higher BMI and abnormal lipid profile characterized 
by increased LDL-cholesterol and total cholesterol when 
compared to patients who have normal pituitary function 
[27]. Moreover, Tanriverdi et al. investigated anthropo-
metric and body composition variables in a population of 
amateur boxers compared to healthy controls. The authors 
found that waist circumference, fat mass and abdominal fat 
mass, as well as serum leptin level were significantly higher 
and IGF-I level was significantly lower in retired boxers as 
compared to healthy non-boxing controls, with high risk for 
cardiovascular complications [61]. Prodam et al. in a cross-
sectional retrospective study in a tertiary care endocrinology 
center, confirmed that TBI patients who developed hypopi-
tuitarism had a worse metabolic profile than TBI patients 
who did not, particularly in terms of altered glucose levels, 
insulin resistance and dyslipidemia, independent of the BMI 
of the patients [28]. The authors confirmed previous data on 
a tendency towards an altered lipid profile in TBI subjects 
with hypopituitarism with elevated triglycerides, but simi-
lar HDL-, LDL- and total cholesterol in both populations. 
The second finding was the high prevalence of fasting or 
postchallenge glucose alterations. This is in line with other 
reports on “classical” hypopituitarism [62, 63], a condition 
marked by higher insulin resistance. The pathophysiologi-
cal mechanism of diabetes and insulin resistance in patients 
with hypopituitarism is not completely understood; however, 
available evidence suggests GH as the principal player due 
to its interaction with many other hormonal and/or peptidic 
systems [59]; in fact, in the study by Prodam et al. GHD was 
the most common anterior hormone deficiency [28]. This 
evidence is confirmed more recently by Giuliano et al. who 
found that in mild TBI patients, increased visceral adipos-
ity and BMI, higher basal glucose, altered lipid profile and 
hypertension were significantly more common in GHD as 
compared to no-GHD patients; moreover VAI, an index of 
insulin resistance and cardiovascular risk was also signifi-
cantly increased in the GHD group [64].
Weight gain is another overlooked event following TBI. 
A longitudinal observational study of Z-score curves in chil-
dren with TBI of mixed severity revealed early weight loss 
followed by a rapid increase in body weight, with 15% of 
children becoming overweight by the time of final assess-
ment [65]. In a study on adult TBI patients presenting with 
sleep-related complaints, 45% exceeded a BMI of 30 kg/
m2 and most complained of having gained weight in the 
time period following TBI [66]. In a longitudinal follow-up 
of adults with TBI, patients could be categorized in three 
weight groups showing stable (30%), loss (28%) and gain 
(42%), with factors related to weight gain being hyperphagia 
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and presence of a dysexecutive syndrome [67]. While mech-
anisms for weight gain after TBI could involve injury to 
hypothalamic centres controlling feeding-satiety and energy 
homeostasis that warrant investigation, other potential fac-
tors could intervene such as loss of circadian rhythms, inac-
tivity secondary to pain or neurological handicap, feature of 
posttraumatic mood disorder, use of corticosteroids to treat 
acute post-traumatic syndrome or use of antiepileptic drugs, 
antidepressants, and psychotropic drugs to treat long-term 
post-traumatic complications.
Treatment
The treatment of TBI-induced hypopituitarism depends on 
the appropriate replacement of the deficient hormones and 
is not different from the treatment of hypopituitarism due 
to other causes [30]. Reversibility of pituitary dysfunction 
in TBI victims should be kept in mind before treatment is 
started, so we can distinguish the treatment in acute and 
chronic phase.
Acute phase
Based on the prospective studies evaluating pituitary func-
tion, most pituitary hormonal changes (especially follicle-
stimulating hormone (FSH)/luteinising hormone (LH), GH 
and thyrotropic hormone (TSH) deficiencies) are transient 
and recover after 3–12 months of injury [15, 17, 19]. Cur-
rently, there is no clear evidence that the replacement of GH, 
FHS/LH and TSH deficiencies in critically ill TBI patients 
during the acute phase is beneficial [3, 68]. However, in the 
acute phase of TBI, the diagnosis of glucocorticoid defi-
ciency should not be missed because it is life-threatening 
[3, 33, 35].
ACTH deficiency
Current evidences suggest that hypothalamus pituitary adre-
nal (HPA) axis insufficiency during the acute phase after 
head trauma is associated with a poor neurological outcome, 
a greater need for vasoactive drug therapy, hyponatremia, 
relative or absolute hypoglycemia, hemodynamic instabil-
ity, and rapidly progressive hypotension, all of which may 
increase the risk of morbidity and mortality [33–35]. There-
fore, the focus during the acute phase of brain injury should 
be on detecting adrenal insufficiency.
On the other hand, the CRASH trial, a large-scale clinical 
study including 10,000 patients with head trauma, and other 
literature reviews have clearly shown that routine administra-
tion of corticosteroids at high doses or pharmacological doses 
to all TBI patients is not indicated or may be harmful [69]. It 
is generally agreed, however, that therapy should be provided 
for patients with confirmed hypoadrenalism in whom clini-
cal circumstances, such as hypotension, hyponatremia, a need 
for higher dose of vasopressors and hypoglycemia, warrant 
intervention [1].
A stress dose of glucocorticoid replacement is mandatory 
in critically ill TBI patients who have ACTH deficiencies. 
The dose of glucocorticoid replacement should be titrated 
based on the clinical status and the requirements of the criti-
cally ill patient. If the patient has adrenal insufficiency and is 
stable, replacement with a physiological dose of hydrocor-
tisone (30 mg/d) could be sufficient initially. When severe 
stress is present and the patient is not stable, 50–100 mg of 
hydrocortisone intravenously (IV) every 8 h (150–300 mg/d; 
stress dose hydrocortisone) or an intravenous (IV) infusion 
of approximately 15 mg/h is recommended [70, 71]. Dexa-
methasone or methylprednisolone could be used alterna-
tively at equivalent hydrocortisone doses. The optimal dura-
tion of corticosteroid supplementation is still not known, but 
it should be continued until the patient’s clinical situation 
has improved and when there is no need for vasopressor 
therapy. When the patient is stable, re-evaluation of the 
ACTH axis is suggested before discharge and a physiologi-
cal dose of glucocorticoid therapy is recommended until the 
second follow-up to establish persistent ACTH deficiency 
[1, 32].
TSH deficiency
The effects of thyroid hormone replacement therapy dur-
ing the acute phase of TBI have not been studied systemati-
cally in clinical studies. Prospective studies demonstrated 
that TSH deficiency generally recovers during or after the 
acute phase [3, 72]. In critically ill burn or medical patients, 
acute thyroid hormone replacement therapy was not shown 
to produce short-term improvement [73]. Therefore, based 
on current evidence, thyroid hormone replacement in the 
acute phase of TBI is not recommended [1, 32].
FSH/LH deficiency
Changes in the gonadotropic axis in the acute phase of TBI 
are mainly an adaptive response and most of the hormone 
deficiencies are transient [3, 17]. Therefore, gonadotropin 
replacement is not recommended in the acute phase [1].
GH deficiency
To date, there has been no clinical study investigating the 
effects of GH replacement therapy in the acute phase of TBI 
in patients with GH deficiency. In a previous randomized, 
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prospective, double-blind, placebo-controlled study by Hat-
ton et al. IGF-I and GH therapy within 72 h of TBI pro-
duced sustained improvement in metabolic and nutritional 
endpoints [74], but GH status of TBI patients in this par-
ticular study was not defined. A large multicenter study by 
Takala et al. showed that the administration of high doses 
of GH in critically ill patients (but TBI patients were not 
included), instead of improving outcome, doubled mortality 
[75]. Experimental studies revealed that GH and IGF-I may 
play a crucial role in brain repair mechanisms or neuronal 
recovery after trauma by regulating the factors including 
neuronal plasticity, myelin formation and vascular tone 
[76]. Moreover, some authors proposed that GH treatment 
may be indicated in every TBI patient in combination with 
rehabilitation, independent of the presence of GH deficiency 
[77, 78]. Thus, GH screening or supplementation is not cur-
rently recommended in the acute phase and during the first 
12 months of TBI [1, 32].
Chronic phase
TSH, FSH/LH and ACTH deficiencies
Patients with hypopituitarism, independent of the etiology, 
require the replacement of deficient hormones as part of 
their standard clinical care. Adequate replacement with glu-
cocorticoids, l-thyroxine and sex steroids generally reverses 
the symptoms and signs of relevant pituitary hormone defi-
ciencies and normalizes the risks associated [3]. Hormone-
replace regimens are the same used for the other causes of 
hypopituitarism [30]. In fact, to date no systematic study has 
been published comparing patients with TBI-induced hypo-
pituitarism and patients with other causes of hypopituitarism 
regarding the effects of the treatment of TSH, FSH/LH and/
or ACTH deficiencies.
In patients with moderate and severe TBI, if there is any 
pituitary hormonal deficiency at the 12th month, appropri-
ate replacement of the deficient hormones is suggested, and 
because the recovery of pituitary dysfunction is extremely 
rare, routine follow-up for the titration of replacement ther-
apy is recommended [1]. If there is no pituitary hormone 
deficiency at the 12th month in patients with moderate/
severe TBI, no further investigation is recommended. How-
ever, it is important to inform these patients regarding the 
symptoms and signs of hypopituitarism, and if they develop 
suspicious signs and symptoms of hypopituitarism they can 
be screened at any time after TBI.
GH deficiency
GH deficiency deserves special attention in TBI patients 
because GH deficiency, isolated GH deficiency in particular, 
is one of the most common pituitary hormone deficits due to 
TBI. Moreover, it is important to emphasize that GH replace-
ment therapy could be beneficial in aiding rehabilitation of 
TBI patients. Recombinant human GH (rhGH) replacement 
therapy, in fact, improves muscle force production, body com-
position, and aerobic capacity [79]. In the latest Endocrine 
Society guideline on the evaluation and treatment of adult GH 
deficiency, patients with GH deficiency and no contraindica-
tions were recommended individualized physiological doses 
of GH treatment (starting dose of 0.2–0.4 mg/d for patients 
younger than 60 years and 0.1–0.2 mg/d for patients older than 
60 years) [70].
The beneficial effects of GH replacement therapy on QoL 
have been investigated in a retrospective German KIMS study 
including patients with TBI and patients with nonfunctioning 
pituitary adenoma (NFPA); it was shown that QoL was signifi-
cantly improved in both groups after GH replacement therapy 
[80]. In addition to the previously mentioned nation-based 
KIMS study, recently Gardner et al. retrospectively assessed 
the clinical characteristics of hypopituitarism due to TBI and 
the QoL measured by QoL-AGHDA scores and the effects 
of long- term GH replacement therapy in a large number of 
TBI patients involved in the KIMS database. When compared 
to NFPA (used as the control group), hypopituitarism in TBI 
victims was biochemically less severe but QoL was worse 
and GH replacement therapy not only significantly improved 
QoL but sustained the relevant improvement in the long-term 
period in patients with TBI [81]. Moreover, a beneficial effect 
on memory and information processing speed [79, 80, 82] and 
an improvement also in verbal processing [83, 84] has been 
recently demonstrated.
In conclusion, current data show that GH replacement 
therapy seems to have beneficial effects in TBI patients as in 
those with other causes of GH deficiency in adults. Therefore, 
at least 12 months after head trauma, an individualized physi-
ological dose of GH replacement therapy in TBI patients with 
severe and sustained GH deficiency is recommend [1, 32]. 
If GH replacement therapy is commenced in GH-deficient 
patients with mild TBI, it is important to keep in mind that 
GH deficiency may recover over a 5 year period after TBI and 
a yearly evaluation of the GH status is necessary. However, 
further placebo-controlled studies with a larger number of 
patients to assess the benefits of treatment with recombinant 
GH in terms of rehabilitation, functional recovery, metabolic 
and cardiovascular risk factor improvement, and neurocogni-
tive/neuropsychological functions in TBI patients are needed.
Conclusion
In conclusion, TBI is a common cause of hypopituitarism. 
An increased level of awareness of TBI-induced hypopi-
tuitarism in the medical community should lead to early 
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diagnosis and, therefore, timely treatment of hypopitui-
tarism, that is a serious but treatable complication of the 
traumatic event. Therefore, close collaboration between 
neurosurgery, endocrinology, rehabilitation medicine is 
essential to ensure optimal delivery of care. Each specialist 
of interested disciplines should keep in mind the clinical 
picture of TBI induced hypopituitarism for a prompt diag-
nosis and adequate treatment. In fact, replacement therapy 
has the potential to improve recovery, rehabilitation, and 
QoL for those patients.
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